Two life sciences powerhouses are coming together to develop an off-the-shelf beta cell replacement therapy for insulin-dependent diabetes patients, which they hope will become a functional cure for both types of the disease.
Biogen is bolstering the company’s multiple sclerosis pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS.
Artios Pharma entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DNA damage response (DDR) targets and enhancing Novartis’ radioligand therapies.
Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program, including the extended half-life cytokine DF6002 as a potential treatment for solid and hematological cancers.
The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.
Biotech company of the year
Autoimmune Disease, Autoimmune Diseases, Biologics License Application (BLA), Biotech, Biotech/Biopharma, Biotechnology, Blockbusters, Clinical Trials, Collaboration, Collaborations, IMS Health, Issue Archives, June 2016, Launches, Launches, Partnership, Partnerships, Patents, Product Launches, R&DImmunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
2016 Annual Report: Top 10 Pipelines
"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemiaThe pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
Zymeworks Announces Antibody Fc Engineering Collaboration and License Agreement with GSK
Autoimmune, Autoimmune Disease, Autoimmune Diseases, Bi-Specific Antibodies, Biotherapeutics, Business, Collaboration, Collaborations, Health, Immune Response, Inflammatory Diseases, Licensing, Licensing, Monoclonal Antibodies, Monoclonal Antibodies, Oncology, R&D, TechnologyVANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. today announced that it has entered into a collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal […]
Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) LONDON & KENILWORTH, N.J.–(BUSINESS WIRE)–GSK and Merck, […]